Zytoprotec

Zytoprotec is a private, pre-revenue biotech start-up developing PDprotec®, a novel peritoneal dialysis fluid designed to be more biocompatible and protective of the peritoneal membrane. The company has completed Phase 1 and 2 trials demonstrating safety and efficacy, and is backed by a world-class Scientific Advisory Board. With significant recent financing, Zytoprotec aims to fund further clinical development to substantiate systemic benefits and position PDprotec® to capture a share of the multi-billion dollar dialysis fluid market.

Proprietary formulation of peritoneal dialysis fluid (PDprotec®) incorporating cytoprotective additives based on hormesis/conditioning principles to protect the peritoneal membrane from damage, reduce inflammation, and improve long-term treatment outcomes.

Competes in the peritoneal dialysis fluid market dominated by large medtech players (e.g., Fresenius Medical Care, Baxter International) offering standard glucose-based and biocompatible (e.g., icodextrin, low GDP) solutions. PDprotec® aims to differentiate by actively protecting the peritoneal membrane, a value proposition not currently addressed by major incumbents.